In 2024, the U.S. stock market experienced robust growth, with the S&P 500 achieving a +23.3% gain, marking its second consecutive year of over 20% returns. This performance was driven by strong consumer spending, a resilient economy, and significant advancements in artificial intelligence (AI), which bolstered technology sector valuations. Despite this incredible market performance, the
The last few months have been characterized by even more momentum than the already impressive first half of the year. We will look at how the Everest Formula has performed relative to the U.S. indices and the market outlook for the months ahead.
For the first time since the beginning of its operational phase, the Everest Formula underperformed the S&P500, registering +6.5% and +0.7% in the 3- and 10-stock strategies, respectively, caused by the boom of mega caps and growth factor for the six-month period. The S&P500 returns +14.7% in the same period.
Everest Formula had a solid performance, slightly beating the S&P500 index even though the index itself performed very well. The 3-stock strategy had a consistent gain of +13.5%, while the 10-stock strategy gained a more limited +11.3%, but with less volatility.
For value investors, this is the best time to find opportunities to catch for the long term and compound their wealth. In this article, we will go over our top five stocks to buy for 2024 that will perform exceptionally well over the long term, starting in 2024.
the Everest Strategy registered a solid average gain of +19.4% in H2-2023, setting the consolidated performance for 2023 at an impressive average of +34.9%, compared to the +24.3% of the S&P500 index. This article reviews the 2023 performance and analyze the best stocks that the Formula discovered in the second half of 2023.
While global equities posted a negative return in Q3, the Everest Formula registered an astounding performance of +19.9% and +9.5% with its 3-stock and 10-stock strategies. In this article, we will analyze the Q3 performance and look at the outlook for the following months.
The 3-stock strategy outperformed the market, registering a +16.6% return compared to the +14.6% recorded by the S&P500 index. The 10-stock strategy, after consistently beating the index in 2022, gives way slightly while still registering a solid +6.6% return.
Pfizer is a big pharma behemoth and has proved its ability to build its COVID vaccine franchise. Despite the current negative market sentiment towards Pfizer, its valuation seems to have reached an attractive level. We will analyze the stock using the most important metrics and by calculating the stock’s intrinsic value.
While many companies can provide a healthy return on investment, some can end up losing you money. In this article, we’ll explore five key factors that can help you identify companies that might not be a good investment choice. The Everest Analyzer is a powerful tool that can help you find some of these weaknesses.
